Medication Adherence And Its Associated Factor: A Cross-Sectional Study Among Patients with Schizophrenia
Abstract
Schizophrenia is a chronic severe psychiatric disorder. Antipsychotic medications are a highly efficacious modality of treating patients with schizophrenia. Non-adherence to antipsychotic medication is a critical problem leading to increased relapse rate, hospitalization rate, and health care costs. Non-adherence is caused by multi-factors and might be varied within the globe. Assessing non-adherence and influencing factors would help in framing preventive strategies. This cross-sectional study involved 100 patients with schizophrenia fulfilling inclusion criteria. Patients’ demographics, clinical parameters, and prescribed drugs were collected. Medication adherence was assessed using the MARS scale (medication adherence rating scale) and symptom severity by PANSS (positive and negative symptom scale). Statistical analysis was done to identify the potential predictors of non-adherence to antipsychotic medication. The correlation of medication adherence with severity of illness was tested. Males were significantly associated with decreased likelihood of being non-adherent with odds ratio of 0.095 (0.014, 0.667) p value of 0.018. An increase in positive and cognitive scores was significantly associated with higher odds of being non-adherent with OR of 1.188 (1.044, 1.325) p-value 0.009 and OR 1.258 (1.073, 1.475) p value 0.005. From this study, non-adherence to medication was noted in 45% of the study population. Thus, strategies need to be framed for regular monitoring and follow-up of female patients on antipsychotics and patients with high PANSS. These steps could reduce the frequency of non-adherence among patients with schizophrenia.
Keywords
Full Text:
PDFReferences
Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS One. 2018;13(4):e0195687.
India State-Level Disease Burden Initiative Mental Disorders Collaborators. The burden of mental disorders across the states of India: the Global Burden of Disease Study 1990-2017. Lancet Psychiatry. 2020 Feb;7(2):148-161.
Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Research. 2010;176(2–3):109–13.
Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste D V. Prevalence of and Risk Factors for Medication Nonadherence in Patients With Schizophrenia. Journal of Clinical Psychiatry. 2002; Oct 15;63(10):892–909.
Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic Medication Adherence in Schizophrenia. Psychiatric Clinics of North America. 2007;30(3):437–52.
Chandra IS, Kumar KL, Reddy MP, Reddy CMPK. Attitudes toward Medication and Reasons for Non-Compliance in Patients with Schizophrenia. Indian Journal of Psychological Medicine. 2014 Jul;36(3):294–8.
Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, de Hert M. Medication adherence in schizophrenia: Factors influencing adherence and consequences of nonadherence, a systematic literature review. Therapeutic Advances in Psychopharmacology. 2013;3(4):200–18.
Saba N, Muraraiah S, H C. Medication adherence in schizophrenia: Understanding patient’s views. National Journal of Physiolology, Pharmacy and Pharmacology. 2019; 9(5): 373-378.
Chaudery B, Saldhana D, Kadiani A, Shahani R. Evaluation of treatment adherence in outpatients with schizophrenia. Industrial Psychiatry Journal. 2017;26(2):215–22.
Kavak F. Determination of Adherence to Treatment of Schizophrenia Patients in Turkey. Annals of Clinical Lababoratory Research. 2018;06(02):1–4.
Ramírez García JI, Chang CL, Young JS, López SR, Jenkins JH. Family support predicts psychiatric medication usage among Mexican American individuals with schizophrenia. Social Psychiatry and Psychiatric Epidemiology. 2006;41(8):624–31
Gilmer TP, Ph D, Dolder CR, Pharm D, Lacro JP, Folsom DP, et al. Adherence to Treatment With Antipsychotic Medication and Health Care Costs Among Medicaid Beneficiaries With Schizophrenia. American Journal of Psychiatry. 2004;161(April):692–9.
Dolder CR, Lacro JP, Dunn LB, Jeste D V. Antipsychotic medication adherence: Is there a difference between typical and atypical agents?. American Journal of Psychiatry. 2002;159(1):103–8.
Yang J, Ko YH, Paik JW, Lee MS, Han C, Joe SH, et al. Symptom severity and attitudes toward medication: Impacts on adherence in outpatients with schizophrenia. Schizophrenia Research. 2012;134(2–3):226–31. Available from: http://dx.doi.org/10.1016/j.schres.2011.11.008
Umut G, Altun ZÖ, Danismant BS, Küçükparlak I, Karamustafalioǧlu N. Relationship between treatment adherence, insight and violence among schizophrenia inpatients in a training hospital sample. Dusunen Adam the journal of psychiatry and neurological sciences. 2012;25(3):212–20.
Tesfaye S, Debencho N, Kisi T, Tareke M. Prevalence of Antipsychotic Polypharmacy and Associated Factors among Outpatients with Schizophrenia Attending Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia. Psychiatry Journal. 2016;2016:1–6.
Stentzel U, van den Berg N, Schulze LN, Schwaneberg T, Radicke F, Langosch JM, Freyberger HJ, Hoffmann W, Grabe HJ. Predictors of medication adherence among patients with severe psychiatric disorders: findings from the baseline assessment of a randomized controlled trial (Tecla). BMC Psychiatry. 2018 May 29;18(1):155.
Tham XC, Xie H, Chng CML, Seah XY, Lopez V, Klainin-Yobas P. Exploring predictors of medication adherence among inpatients with schizophrenia in Singapore’s mental health settings: A non-experimental study. Archives of Psychiatry Nursing. 2018 Aug;32(4):536-548.
Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry. 2008 Apr 30;8:32.
Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013 Oct;12(3):216-26
DOI: https://doi.org/10.15416/pcpr.v7i1.35121
Refbacks
- There are currently no refbacks.
